Abstract 2237P
Background
This trial explores the clinical efficacy and safety of AVE, CET and IRI for treatment refractory MSS mCRC. We aim at characterizing the immune response for biomarker discovery through associated translational research.
Methods
MSS, chemorefractory (anti-EGFR refractory if RAS wt) mCRC patients (pts) were enrolled (RAS wt: 28 pts, RAS mut: 27 pts) and treated with CET and IRI from week 1(W1) and AVE from W3. Clinical objectives (safety, tumor response, disease control rate (DCR), PFS and OS) were presented separately. Exploratory endpoints include predictive efficacy biomarkers (immunoscore (IS), immune tumor microenvironment, gene expression profile (GEP), ctDNA) and modification overtime. Multiplex immunofluorescence (MIF), RNAseq and ctDNA analyses were done (sequential metastasis biopsies and plasma samples at W0, W3, W11). CD3, CD8, CD45RO, PD1, PD-L1cells densities were quantified. RNA-seq data were used to perform several analyses (DESeq2, GSEA, deconvolution, gene ontology). OncoSELECT panel (58 genes) was used to follow ctDNA variation over time (mean variant allele frequency).
Results
Among 55 treated pts, 95 biopsies (W0: 39, W3: 29, W11: 27) were available for MIF (table: W0 results). On 23 pts (1st stage), upregulation of adaptive immune response signature was associated with tumor shrinkage, PFS>6 and OS>12 months (p. adj= 0.00). Few modifications of immune cells and GEP were observed overtime (W0, W3, W11). ctDNA decrease (>10%) was associated with tumor response (p=0.04) and PFS (6.6 vs 3.4 months, p=0.08). Table: 2237P
| Characteristics | IS (CD3/CD8) high | CD3/PD1 high | CD3/CD8/CD45RO/PD1 high |
| High/others:pts | 10/29 | 10/29 | 8/31 |
| RAS-wt/RAS-mut:OR, p-v | 1.39, p=0.73 | 0.82, p=0.99 | 0.83, p=0.99 |
| Tumor shrinkage: OR, p-v | 8.32, p=0.00 | 4.50, p=0.05 | 9.54, p=0.00 |
| DCR:OR, p-v | 8.02, p=0.05 | 3.16, p=0.26 | 5.55, p=0.12 |
| PFS:HR, p-v | 0.29, p=0.00 | 0.28, p=0.00 | 0.43, p=0.03 |
| OS:HR, p-v | 0.62, p=0.19 | 0.26, p=0.00 | 0.47, p=0.06 |
Conclusions
Independently of RAS mutation, existing adaptive immune response within metastases is associated with treatment benefit. ctDNA decrease is associated with tumor response.
Clinical trial identification
NCT03608046.
Editorial acknowledgement
Legal entity responsible for the study
Cliniques Universitaires Saint-Luc (Pr. MD. PhD. Marc van den Eynde).
Funding
Merck Serono.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2183P - The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients
Presenter: Adam Chapman
Session: Poster session 07
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07